KIMCo Signs Information Partnership Agreement with iEvaluate for Pharmaceutical and Bio Industry

At the Pharmaceutical Hall in Seocho-gu, Seoul, Heo Kyunghwa, CEO of KIMCo (left), and Stefan Elder, Vice President of Evaluate Asia Pacific, are signing a business agreement and taking a commemorative photo.

[Asia Economy Reporter Lee Gwan-joo] The Korea Innovative Medicines Consortium (KIMCo), a foundation, announced on the 19th that it recently signed a Memorandum of Understanding (MOU) with Evaluate to collaborate in the field of global pharmaceutical and bio-industry information.

Through this strategic partnership, KIMCo and Evaluate aim to enhance the accessibility of domestic pharmaceutical and bio companies to trends in the global pharmaceutical and bio-industry, including global research and development (R&D), clinical trials, regulatory approval, technology transfer, mergers and acquisitions (M&A), and market demand forecasting. They plan to support domestic companies' global expansion based on more accurate information.

Evaluate, established in the UK in 1996, provides global pharmaceutical and bio-industry analysis and consulting services to pharmaceutical companies, bio-venture firms, investors, research institutions, and public organizations worldwide.

Stefan Elder, Vice President of Evaluate Asia Pacific, said, "Accelerating innovative drug development and improving patient access to new drugs is Evaluate's mission. Through close cooperation with KIMCo, we support Korean pharmaceutical and bio companies in establishing commercialization strategies and ultimately expect to promote global open innovation for Korean companies."

Heo Kyung-hwa, CEO of KIMCo, stated, "Market and technology data research is essential for strategic planning in global new drug R&D and commercialization. Through cooperation with Evaluate, we plan to strengthen domestic pharmaceutical and bio companies' capabilities in global market information and actively support the global expansion of domestic pharmaceutical companies."

This content was produced with the assistance of AI translation services.